Connect with us

Hi, what are you looking for?


FDA is Eyeing Steps For a Rapid Review of Vaccines Specific To Omicron, CDC Director Says

The Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky confirmed that the Food and Drug Administration (FDA) was eyeing steps for the rapid review in the discussions of specific vaccines for Omicron

 CDC director confirms FDA in talks to streamline authorization of omicron-specific vaccine (Photo stockxpo)

The director of CDC confirmed that the FDA was eyeing steps for a rapid Review in the discussions of an omicron-specific vaccine.

FDA is Looking for Vaccines Specific for Omicron

The co-anchor Martha Raddatz of “This Week” asked Rochelle Walensky the CDC Director on ABC news quoting  “Is there any world where you can see that moves faster given that we have already been through this? ” the news co-anchor was referring to the Pfizer, Moderna, Johnson, and Johnson where the vaccine maker company can do it very quickly in three months by giving out the specific vaccine for the new strain omicron.

In addition, Walensky answered that she needs to defer to the FDA, though they’ve already had a conversation to streamlining the authorization of a specific vaccine for omicron, partially “because all of the vaccines is usually the same, and it would just be that mRNA code that would need to change”.

Moreover, Wilensky did confirm that FDA is eyeing all the drugmakers to studies, to the case of vaccines that would match for the Omicron, and examine hundreds of people and their immune responses in comparison to the coronavirus test trials that rely on the COVID-19 novel to be detected and to include thousands of participants.

FDA Sighted a Statement

To acknowledge the question wherein the report by the Journal about FDA’s plan, as a result of Janet Woodcock, pointed out a statement last week by the acting commissioner for the FDA’s latest plan towards vaccine development to address variants. Furthermore, the agency’s vaccine emergency use authorization guidance was last updated in February.

Hence, the job that needs to acquire is the genetic information and patient samples for variants knowing has a high level of mutation. Then after performing the testing that needs to evaluate the impact. Thus, FDA said that it needs some time to determine the effect of the variant. However, they are expecting the vast majority of the work to be completed by the following weeks.